Significant improvement of specific bronchial hyperreactivity in asthmatic children after 4 months of treatment with a modified extract of Dermatophagoides pteronyssinus

Journal of Investigational Allergology and Clinical Immunology

Volumn 16, Issue 3, 2006, Pages 194-202

  Ibero, M ^a   Castillo, M J ^a  

^a HOSPITAL DE TERRASSA   (Spain)

Author keywords

Allergoids; Asthma; Dermatophagoides pteronyssinus; Hyperreactivity; Immunotherapy; Modified allergens

Indexed keywords

DEPIGOID; HOUSE DUST ALLERGEN; VACCINE;

ADOLESCENT; ALLERGIC ASTHMA; ARTICLE; BRONCHUS HYPERREACTIVITY; BRONCHUS REACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOPHAGOIDES PTERONYSSINUS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEAT; HOUSE DUST ALLERGY; HUMAN; IMMUNOTHERAPY; INJECTION SITE INFLAMMATION; MAINTENANCE THERAPY; MALE; PAIN; POLYMERIZATION; PRURITUS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCHOOL CHILD; SIDE EFFECT; SKIN INDURATION; SKIN MANIFESTATION; SKIN TEST;

ADOLESCENT; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHIAL PROVOCATION TESTS; CHILD; DERMATOPHAGOIDES PTERONYSSINUS; DESENSITIZATION, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; SKIN TESTS; TREATMENT OUTCOME;

EID: 33745219481     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. WHO Position Paper. Allergy. 1998;53 (Suppl 54):1-42.
2. Malling HJ, Weeke B. EAACI Position paper: Immunotherapy. Allergy 1993;48(14 Suppl):7-35.
3. Bousquet J, Michel FB. Specific immunotherapy in asthma: is it effective? J Allergy Clin Immunol. 1994;94(1):1-11.
4. Golden DB, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Dose dependence of Hymenoptera venom immunotherapy. J Allergy Clin Immunol. 1981;67(5):370-4.
5. Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol. 1993;91(3):709-22.
6. Mosbech H, Osterballe O. Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy. 1988;43(7):523-9.
7. Horst M, Hejjaoui A, Horst V, Michel FB, Bousquet J. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J-Allergy-Clin-Immunol. 1990;85(2):460-72.
8. Ferrer A, García-Sellés J. Significant improvement in symptoms, skin test, and specific bronchial reactivity after 6 months of treatment with a depigmented, polymerized extract of Dermatophagoides pteronyssinus and D. farinae. J Invest Allergol Clin Immunol. 2003;13(4):244-51.
9. Gardner LM, Thien FC, Douglass JA, Rolland JM, O'Hehir RE. Induction of T 'regulatory' cells by standardized house dust mite immunotherapy: an increase in CD4+ CD25+ interleukin-10+ T cells expressing peripheral tissue trafficking markers. Clin Exp Allergy. 2004;34(8):1209-19.
10. Hung CH, Lee MY, Tsai YG, Cheng SN, Yang KD. Hyposensitization therapy reduced exhaled nitric oxide in asthmatic children with corticosteroid dependency. Acta Paediatr Taiwan. 2004;45(2):89-93.
11. Guerra F, Daza JC, Almeda E. Immunotherapy with a depigmented, polymerized vaccine of Olea europaea pollen allergens significantly reduces specific bronchial and skin test reactivity in sensitized patients after one year of treatment. J Investig Allergol Clin Immunol. 2003;13(2):108-17.
12. García-Sellés J, Pascual A, Funes E, Pagán JA, López JD, Negro JM, Hernández J. Clinical efficacy and safety of a depigmented and glutaraldehyde polymerized therapeutic vaccine of Parietaria judaica. Allergol Immunopathol (Madrid). 2003;31(2):63-9.
13. Vray M. Pragmatic and Explanatory Trials. Ask and Answer Different Questions. Applied Clinical Trials 1999:42-50.
14. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis. 1967;20(8):637-48.
15. NHLBI/WHO Workshop Report: Global Strategy for Asthma Management and Prevention. NHLMI publication no. 02-3659. Bethesda, Maryland, USA. 1995.
16. Martí-Guadaño E, Oau-Casanovas L, Vila-Indurain B, Marañón F, Fernández-Caldas E. Sensitization and Exposure to Mite Allergens in Asthmatic Children Seen With a Recurrent Acute Exacerbation of Their Asthma, and in Controls, in an Emergency Room in Badalona, Spain. J Allergy Clin Immunol. 2000;105:ps 687.
17. Patterson R, Suszko IM, Pruzansky JJ, Zeiss CR. Polymerized ragweed antigen e. ii. in vivo elimination studies and reactivity with IgE antibody systems. J Immunol. 1973;110(5):1413-8.
18. Patterson R, Suszko IM, McIntire FC. Polymerized ragweed antigen E. I. Preparation and immunologic studies. J Immunol 1973;110(5):1402-12.
19. Sachs DH, Winn HJ. The use of glutaraldehyde as a coupling agent for ribonuclease and bovine serum albumin. Immunochemistry. 1970;7(6):581-5.
20. Casanovas M, Bel I, Marañón F, Berrens L. Estimation of IgE antibodies to the common allergens by reverse enzyme immunoassay. Comparison with the radioallergosorbent test. J Investig Allergol Clin Immunol. 1991;1(4):247-52.
21. Casanovas M, Marañón F, Bel I. Comparison of skin-prick test assay and reverse enzyme immunoassay competition (REINA-C) for biological activity of allergens. Clin Exp Allergy. 1994;24(2):134-9.
22. Boluda L, Gallego MT, González-Romano ML, Cambra O, Berrens L. Evaluation of the potency of allergenic extracts by inhibition of IgG-antibody binding. Biologicals. 1994;22(2):171-7.
23. Cockcroft DW, Killian DN, Mellon JJ, Hargreave FE. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy. 1977;7(3):235-43.
24. Frolund L. Bronchial allergen challenge methodological studies. Allergy 1996;51(29 Suppl):1-41.
25. Nordic-Council-on-Medicines. Registration of allergen preparations. Nordic -guidelines. Prepared by the Nordic Council on Medicines in cooperation with the Drug Regulatory Authorities in Denmark, Finland, Iceland, Norway and Sweden. NLN Publication No. 23 1989;Ed. January:1-36.
26. Dreborg S, Belin L, Eriksson NE, Grimmer O, Kunkel G, Malling HJ, Nilsson G, Sjogren I, Zetterstrom O. Results of biological standardization with standardized allergen preparations. Allergy. 1987;42(2):109-16.
27. Belin L. Biologic standardization - the HEP unit. In: Arb Paul Ehrlich Inst Georg Speyer Haus Ferdinand Blum Inst Frankf A M; 1987. p. 145-53.
28. Dreborg S, Agrell B, Foucard T, Kjellman NI, Koivikko A, Nilsson S. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results. Allergy. 1986;41(2):131-40.
29. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. Journal Of Chronic Diseases. 1967;20(8):637-48.
30. Schwartz D, Flamant R, Lellouch J. Clinical Trials. London: Academic Press; 1980.
31. Cropp GJ. Relative sensitivity of different pulmonary function tests in the evaluation of exercise-induced asthma. Pediatrics. 1975;56(5 pt-2 suppl):860-7.
32. Fish JE, Kelly JF. Measurements of responsiveness in bronchoprovocation testing. J Allergy Clin Immunol. 1979;64(6 pt 2):592-6.
33. Kopferschmitt-Kubler MC, Bigot H, Pauli G. Allergen bronchial challenge tests: variability and reproducibility of the early response. J Allergy Clin Immunol. 1987;80(5):730-40.
34. Spector S, Luparello TJ, Kopetzky MT, Souhrada J, Kinsman RA. Response of asthmatics to methacholine and suggestion. Am Rev Respir Dis. 1976;113(1):43-50.
35. World Medical Association Declaration of Helsinki. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Note of Clarification on Paragraph 29 added by the WMA General Assembly, Washington 2002. Ethical Principles for Medical Research Involving Human Subjects. http://www.wma.net/e/policy/pdf/17c. pdf. 2002.
36. Metzger WJ, Zavala D, Richarson HB, Moseley P, Iwamota P, Monick M, Sjoerdsma K, Hunninghake GW. Local allergen challenge and bronchoalveolar lavage of allergic asthmatic lungs. Description of the model and local airway inflammation. Am Rev Respir Dis. 1987;135(2):433-40.
37. De Monchy JG, Kauffman HF, Venge P, Koeter GH, Jansen HM, Sluiter HJ, De Vries K. Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev Respir Dis. 1985;131(3):373-6.
38. Robinson D, Hamid Q, Bentley A, Ying S, Kay AB, Durham SR. Activation of CD4+ T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J Allergy Clin Immunol. 1993;92(2):313-24.
39. Hendeles L, Harman E. Use of allergen bronchoprovocation to screen drugs for anti-asthma activity. Pharmacotherapy. 1997;17(1 Pt 2):39S-49S.
40. Metzger WJ, Hunninghake GW, Richerson HB. Late asthmatic responses: inquiry into mechanisms and significance. Clin Rev Allergy. 1985;3(2):145-65.
41. Van Bever HP, Stevens WJ. Suppression of the late asthmatic reaction by hyposensitization in asthmatic children allergic to house dust mite (Dermatophagoides pteronyssinus). Clin Exp Allergy. 1989;19(4):399-404.
42. Van Bever HP, Stevens WJ. Evolution of the late asthmatic reaction during immunotherapy and after stopping immunotherapy. J Allergy Clin Immunol. 1990;86(2):141-6.
43. Van Bever HP, Bosmans J, De Clerck LS, Stevens WJ. Modification of the late asthmatic reaction by hyposensitization in asthmatic children allergic to house dust mite (Dermatophagoides pteronyssinus) or grass pollen. Allergy. 1988;43(5):378-85.
44. Arvidsson MB, Lowhagen O, Rak S. Allergen specific immunotherapy attenuates early and late phase reactions in lower airways of birch pollen asthmatic patients: a double blind placebo-controlled study. Allergy. 2004;59(1):74-80.
45. Warner JO, Price JF, Soothill JF, Hey EN. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet .1978;2(8096):912-5.
46. Ibero M, Ridao M, Artigas R, Treserras R, Casanovas M. Immunotherapy with an extract standardized and with an allergoid of D. pteronyssinus. Evolution of the bronchial specific and unespecific reactivity. Allergy Clin Immunol News. 1994;Supl. 2:390.